Scancell Share Discussion Threads

[18bt] 19/9/2023 09:26

Amazed no comment so far on today’s announcement. V encouraging.

[inanaco] 19/9/2023 09:23

the uk market sold Arm to the japanese who sold it to the Americans

who lost ?

British investors

short sighted, useless at research, and worse constant negative outlook

in fact the ultimate UK investor badge must go to

Lozan

[babbler] 19/9/2023 09:19

In USA this would have bagged by now today.

[inanaco] 19/9/2023 09:10

SCIB1 never cured the mouse ............

Iscib1 did

[markingtime] 19/9/2023 09:08

Indeed it is still cheap. I expect a ten-fold rise over the next year from the present 16p.

[marcusl2] 19/9/2023 08:51

According to Trinity Delta, the study's success is even more impressive when compared to other treatments.

Usually, the best results seen in this type of advanced skin cancer are around a 48-58% success rate.

Scancell's study is now moving to the next phase, where it plans to treat 27 more patients.

The company also plans to test an enhanced version of the vaccine, which could potentially work for all skin cancer patients and is more potent.

Trinity Delta expects data from these new tests by the first half of 2024. It also noted that Scancell is likely to explore partnerships and other business deals, given the strength of these results.

The research currently values Scancell at £300.1 million, or 36.7 pence per share.

[chillpill] 19/9/2023 08:48

I was a shareholder in BB Biotech back in 1996 when US investors got excited and to it to a market cap of $2.5 billion (big enough for FTSE 100) and they were at the pre-clinical stage.

Let’s hope for some mainstream press coverage on this stunning (early) data.

[inanaco] 19/9/2023 08:47

"""In addition to SCIB1, Scancell expects significant results from its other programmes in 2024 including top-line Modi-1 CPI combination data and attractive out-licensing opportunities from the GlyMab® and AvidiMab® platforms."""

get ready for the next event

""""""""" top-line Modi-1 CPI combination data """"""


Synonyms of top line (adj.

excellent. exceptional. high-quality. marvelous. outstanding.

[miavoce] 19/9/2023 08:45

Zac Mir's forecast (a few weeks ago) of 20p by end Sept is looking very doable.

[marcusl2] 19/9/2023 08:39

Research house Trinity Delta said: "Although a small patient population, these highly impressive data from the SCOPE study effectively demonstrate the concept of using the SCIB vaccine in combination with CPIs.

"The strength of the results means the second stage of the study, treating a further 27 patients (bringing the total to 43), has a 90% probability of success.

"In parallel, a new patient cohort will examine the same CPI doublet in combination with iSCIB1+, which offers broader patient applicability and greater potency."

Professor Poulam Patel, the chief investigator, said: "These results if confirmed in a larger cohort, will significantly improve upon current treatment options. We are eager to proceed to the second stage of the study and will report additional data in due course."

[marcusl2] 19/9/2023 08:32

and that was not with doublet, only Keytruda!


Oct 22
Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million.

How much for the Immunobody platform and use of Avidimab?

[inanaco] 19/9/2023 08:29

advice

its so cheap ....... even at 37p trinity values

atb

[inanaco] 19/9/2023 08:28

just to put that into context ......... if i had been wrong it would have cost me £130,000 of capital

as big mama says Money talks

LOL

[inanaco] 19/9/2023 08:21

and scancell did it as a standalone ..........

[marcusl2] 19/9/2023 08:18

. In a Phase 1/2 clinical trial, 14 out of 16 resected
patients (89%) survived for more than 5 years following vaccination with SCIB1.
The original Phase 2 study was designed to assess whether the addition of SCIB1 treatment to pembrolizumab results in an improvement in patient outcomes for patients with metastatic disease.

[marcusl2] 19/9/2023 08:15

For any newbies, Scib is off the shelf. Merck / Moderna is personalised.

iScib with Avidimab will be a further improvement and cover ALL patients.

[inanaco] 19/9/2023 08:14

Marcus scancell from memory was 88% in the same setting "resected"

[torquayfan] 19/9/2023 08:14

Plasbryn - IMO the endpoint for the impact of this data will not be diminished in any way by the release today of this RNS . . . an alternative view would be that matters are now nicely primed for Prof. Lindy at Cicon Milan - Scancell are ready to turn on the afterburners later this week.

[marcusl2] 19/9/2023 08:13

Plenty of the big boys will want Immunobody and Avidimab. Don`t forget about Moditope and the Glymabs !!

[marcusl2] 19/9/2023 08:11

Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection


Scancell...

Key Highlights

-- SCOPE trial surpasses its first milestone with an 82% response rate
-- To our knowledge no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma


( one is resected the other unresected )

[babbler] 19/9/2023 08:08

Vastly derisked data here. Very nice. Should really move on higher. Half the mcap of AVCT and more advanced?Of course you get sell on news brigade but really good update.

[markingtime] 19/9/2023 08:06

Plasbryn,They were always going to have to update the market on the SBIB data - and indeed they said they would.Question is, will there be a Modi-1 update too?On the "market price" aspect, we are getting closer to having a properly-informed market. The last few months are now being proven to have been irrelevant, as I'd pointed out - simply because nobody who was buying or selling knew the trial data.

[inanaco] 19/9/2023 08:01

10 years of Scib1 ....... no risk

which one has failed posts

LOL

devastating news for the "this is risky brigade"

i also told you SCIB1 is the backstop ........... and explained why

[torquayfan] 19/9/2023 07:58

Ruck - re. "I wonder if the RNS had to be brought forward because the cat was out the bag? " Good point but I guess it would be hard to contain news of this significance.

I doubt that the endpoint for the 'impact' will be any lower because of this RNS today.